ADMA Reports FDA Approval Expanding ASCENIV Label to Pediatric Patients 2+ Years, $12M Revenue, +15% YoY Growth
ADMA Biologics, Inc. · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $7.90
-18% in 3d after detection
Post-detection moves
1h
—
1d
-0.6%
3d
-18%
7d
-18%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS